Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A5 | Q15758 | 1/20 | 0.38 |
| ▸ | NOS3 | P29474 | 1/20 | 0.37 |
| ▸ | NOS1 | P29475 | 1/20 | 0.37 |
| ▸ | NOS2 | P35228 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 2/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.34 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.34 |
| ▸ | GFPT1 | Q06210 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | GRIK1 | P39086 | 6/20 | 0.32 |
| ▸ | GRIK2 | Q13002 | 5/20 | 0.32 |
| ▸ | GSR | P00390 | 2/20 | 0.32 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.32 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.32 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.32 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.32 |
| ▸ | GRIA4 | P48058 | 2/20 | 0.32 |
| ▸ | GRIK3 | Q13003 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Azaserine SCHEMBL8862 | 1.00 | SLC1A5 (0.38) | SLC1A5NOS3NOS1NOS2IDO1 | |
| Azaserine SCHEMBL8861 | 1.00 | SLC1A5 (0.38) | SLC1A5NOS3NOS1NOS2IDO1 | |
| Azaserine SCHEMBL3312110 | 1.00 | SLC1A5 (0.38) | SLC1A5NOS3NOS1NOS2IDO1 | |
| Azaserine SCHEMBL27500218 | 0.98 | SLC1A5 (0.37) | SLC1A5NOS3NOS1NOS2IDO1 | |
| Azaserine SCHEMBL607082 | 0.98 | SLC1A5 (0.37) | SLC1A5NOS3NOS1NOS2IDO1 | |
| SCHEMBL607081 | 0.84 | — | — | |
| Azaserine SCHEMBL6824548 | 0.82 | ALOX15 (0.47) | NOS3NOS1NOS2CYP1A2GRIK1 | |
| SCHEMBL31237462 | 0.81 | IDO1 (0.40) | SLC1A5NOS3NOS1NOS2IDO1 | |
| SCHEMBL26934495 | 0.81 | IDO1 (0.40) | SLC1A5NOS3NOS1NOS2IDO1 | |
| Azaserine SCHEMBL81760 | 0.78 | ALDH1A1 (0.41) | SLC1A5IDO1SLC7A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120035105-A1 | Insulin Therapies for the Treatment of Diabetes, Diabetes Related Ailments, and/or Diseases or Conditions Other Than Diabetes or Diabetes Related Ailments | SDG, INC. | 2012-02-09 | — | — | US | disclosed |
| EP-2410991-A1 | ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS | SDG, INC. (an Ohio Corporation ) (US) | 2012-02-01 | — | — | EP | disclosed |
| WO-2011119953-A1 | METHODS AND COMPOSITIONS FOR WEIGHT LOSS | SDG, INC. (US) | 2011-09-29 | — | — | WO | disclosed |
| US-20110135727-A1 | Hepatocyte Delivery Vehicle for Delivery of a Combination of Recombinant Human Regular Insulin and Recombinant Human Insulin Isophane to a Mammal | SDG, INC. | 2011-06-09 | — | — | US | disclosed |
| US-20110135725-A1 | Lipid Construct for Delivery of Insulin to a Mammal | SDG, INC. (US) | 2011-06-09 | — | — | US | disclosed |
| WO-2011022396-A1 | LIPID CONSTRUCT FOR DELIVERY OF INSULIN TO A MAMMAL | SDG, INC. (US) | 2011-02-24 | — | — | WO | disclosed |
| US-7871641-B2 | Hepatocyte-targeting vehicle for delivery of glargine insulin to a mammal | SDG, INC. (US) | 2011-01-18 | — | — | US | disclosed |
| US-20100113386-A1 | N-BENZYL SUBSTITUTED PYRIDYL PORPHYRIN COMPOUNDS AND METHODS OF USE THEREOF | INOTEK PHARMACEUTICALS CORPORATION (US) | 2010-05-06 | — | — | US | disclosed |
| US-7642250-B2 | N-benzyl substituted pyridyl porphyrin compounds and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION (US) | 2010-01-05 | — | — | US | disclosed |
| EP-1928467-A2 | N-BENZYL SUBSTITUTED PYRIDYL PORPHYRIN COMPOUNDS AND METHODS OF USE THEREOF | Inotek Pharmaceuticals Corporation (US) | 2008-06-11 | — | — | EP | disclosed |
| WO-2007038630-A2 | N-BENZYL SUBSTITUTED PYRIDYL PORPHYRIN COMPOUNDS AND METHODS OF USE THEREOF | INOTEK PHARMACEUTICALS CORPORATION (US) | 2007-04-05 | — | — | WO | disclosed |
| US-20070072825-A1 | N-benzyl substituted pyridyl porphyrin compounds and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION (US) | 2007-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113386-A1 | N-BENZYL SUBSTITUTED PYRIDYL PORPHYRIN COMPOUNDS AND METHODS OF USE THEREOF | PPOX, PPIF, COX5A | SLC1A5 1172/4885NOS3 330/4885NOS1 190/4885 |
| US-20120035105-A1 | Insulin Therapies for the Treatment of Diabetes, Diabetes Related Ailments, and/or Diseases or Conditions Other Than Diabetes or Diabetes Related Ailments | IAPP, IDE, INSR | SLC1A5 1469/4885NOS3 3719/4885NOS1 3890/4885 |
| US-20070072825-A1 | N-benzyl substituted pyridyl porphyrin compounds and methods of use thereof | PPOX, PPIF, COX5A | SLC1A5 1172/4885NOS3 330/4885NOS1 190/4885 |
| US-20110135725-A1 | Lipid Construct for Delivery of Insulin to a Mammal | INSR, IAPP, GPR119 | SLC1A5 730/4885NOS3 4705/4885NOS1 4685/4885 |
| US-20110135727-A1 | Hepatocyte Delivery Vehicle for Delivery of a Combination of Recombinant Human Regular Insulin and Recombinant Human Insulin Isophane to a Mammal | INSR, INSRR, IAPP | SLC1A5 1698/4885NOS3 3373/4885NOS1 2507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.